| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ATRA | FIMM | pan-cancer | AAC | -0.032 | 0.8 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.8 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |
| mRNA | QL-XII-61 | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | azacitidine | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.9 |